WINT
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Windtree announces interim analysis of Istaroxime Phase 2 in SCAI Stage C cardiogenic shock patientsAug 5, 2025
- Windtree announces issuance of U.S. patent for Istaroxime in acute heart failureJul 2, 2025
- Windtree announces Istaroxime Phase 2 cardiogenic shock study meets enrollment target for interim analysisJul 1, 2025
- Windtree publishes positive Phase 2 SEISMiC B study results for istaroximeJun 16, 2025
- Windtree Therapeutics plans interim results for Phase 2 trial of Istaroxime in cardiogenic shock (SCAI Stage C) by July 2025May 22, 2025